Tradestie Institutional Equity Comparison Engine
ENTX vs COCP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, ENTX sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs COCP N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin 0.0% vs -3063.6% ยท YoY -100.0% vs +26.9%
Momentum & Technical Winner
ENTX
1Y +10.7% vs -1.9% ยท 52W Pos 64% vs 20%
Options & Structure Winner
ENTX
CONSOLIDATION (30th %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.00
-0.66% 1D
Market Cap
$541.6M
1M Return
+2.04%
1Y Return
+10.7%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.3% 1D
Market Cap
$18.9M
1M Return
+6.7%
1Y Return
-1.94%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +10.7%
COCP -1.94%
Spread: +12.64 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | COCP Revenue | ENTX Op. Margin | COCP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | N/A | $10M | N/A | -30.6% | COCP |
| FY2019 | N/A | $10M | N/A | -737.4% | COCP |
| FY2020 | $0M | $0M | -3059.7% | -476.0% | COCP |
| FY2021 | $0M | N/A | -2139.6% | N/A | ENTX |
| FY2022 | $0M | N/A | -9714.2% | N/A | ENTX |
| FY2024 | $0M | N/A | -5295.6% | N/A | ENTX |
| FY2025 | $0M | N/A | -27450.0% | N/A | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | COCP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $541.6M | $18.9M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +26.9% | Higher Growth | COCP |
| Operating Margin (TTM) Profitability | 0.0% | -3063.6% | Higher Margin | ENTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -311.7% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 64% ($1โ$4) | 20% ($1โ$2) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.07ฮฒ ยท 45% Vol | 0.98ฮฒ ยท 54% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 38.7 / 100 (SELL) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs COCP Buy Guide
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
30th %ile
IV Regime
Balanced (25thโ60th %ile)
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.